We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-13.49%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$298M
AUM Growth
-$121M
(-29%)
Cap. Flow
-$4.12M
Cap. Flow
% of AUM
-1.38%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
104
New
36
Increased
13
Reduced
16
Closed
35
Avg Time Held Equity + Options
0.4
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$23.2M |
| 2 |
Envista
NVST
|
+$21.9M |
| 3 |
Boston Scientific
BSX
|
+$15.5M |
| 4 |
Biogen
BIIB
|
+$12.7M |
| 5 |
SPDR Gold Trust
GLD
|
+$9.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$16.7M |
| 2 |
Pfizer
PFE
|
+$14.9M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$14.8M |
| 4 |
Gilead Sciences
GILD
|
+$12.1M |
| 5 |
GSK
GSK
|
+$9.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.97% |
| 2 | Miscellaneous | 13.13% |
| 3 | Financials | 0.58% |
| 4 | Technology | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$235B
| $21.5M | 7.21% |
+106,069
| New | +$23.2M |
2020 Q1
0 quarters
|
|
2
McKesson
MCK
$116B
| $17.9M | 6% |
132,340
+63,901
| +93% | +$9.36M |
2019 Q3
2 quarters
|
|
3
Coherus Oncology
CHRS
$165M
| $17.5M | 5.86% |
1,077,839
+131,078
| +14% | +$2.42M |
2019 Q2
3 quarters
|
|
4
PUT
CEL-SCI Corp
CVM
$30.6M
| $15M | 5.04% |
43,437
-7,483
| -15% | -$2.74M |
2019 Q3
2 quarters
|
|
|
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $14.7M | 4.93% |
168,044
-17,713
| -10% | -$1.88M |
2018 Q4
5 quarters
|
|
|
6
Biogen
BIIB
$34.8B
| $13.3M | 4.45% |
+41,938
| New | +$12.7M |
2020 Q1
0 quarters
|
|
7
Elevance Health
ELV
$92.9B
| $13.1M | 4.4% |
57,869
+27,130
| +88% | +$7.39M |
2019 Q2
3 quarters
|
|
|
8
Boston Scientific
BSX
$64B
| $12.9M | 4.33% |
+395,747
| New | +$15.5M |
2020 Q1
0 quarters
|
|
|
9
Envista
NVST
$3.77B
| $12.8M | 4.29% |
+856,922
| New | +$21.9M |
2020 Q1
0 quarters
|
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $9.74M | 3.26% |
55,000
-41,931
| -43% | -$7.9M |
2019 Q3
2 quarters
|
|
|
11
SPDR Gold Trust
GLD
$142B
| $9.58M | 3.21% |
+64,702
| New | +$9.63M |
2020 Q1
0 quarters
|
|
12
United Therapeutics
UTHR
$23.2B
| $8.61M | 2.89% |
90,823
-41,841
| -32% | -$3.98M |
2018 Q4
5 quarters
|
|
13
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $8.54M | 2.86% |
+2,246,900
| New | +$7.4M |
2020 Q1
0 quarters
|
|
14
Vanda Pharmaceuticals
VNDA
$256M
| $7.47M | 2.5% |
+721,193
| New | +$8.94M |
2020 Q1
0 quarters
|
|
15
Merck
MRK
$358B
| $7.16M | 2.4% |
97,551
-80,352
| -45% | -$6.32M |
2019 Q4
1 quarter
|
|
16
HCA Healthcare
HCA
$101B
| $7M | 2.35% |
77,932
-31,667
| -29% | -$4.1M |
2018 Q1
8 quarters
|
|
17
NovaBridge Biosciences American Depositary Shares
NBP
$149M
| $6.14M | 2.06% |
+472,675
| New | +$5.91M |
2020 Q1
0 quarters
|
|
18
UnitedHealth
UNH
$365B
| $5.46M | 1.83% |
+21,900
| New | +$6.03M |
2020 Q1
0 quarters
|
|
19
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| $5.14M | 1.72% |
+572,681
| New | +$5.87M |
2020 Q1
0 quarters
|
|
20
DELISTED
Radius Health, Inc.
RDUS
| $5.04M | 1.69% |
387,402
+287,402
| +287% | +$5.12M |
2019 Q4
1 quarter
|
|
21
Molina Healthcare
MOH
$11.1B
| $5.03M | 1.68% |
35,973
-37,263
| -51% | -$4.99M |
2018 Q4
5 quarters
|
|
22
Zimmer Biomet
ZBH
$18B
| $4.75M | 1.59% |
+48,410
| New | +$6.35M |
2020 Q1
0 quarters
|
|
23
Quanterix
QTRX
$145M
| $4.36M | 1.46% |
+237,081
| New | +$5.41M |
2020 Q1
0 quarters
|
|
24
Lite Strategy Inc
LITS
$36.5M
| $4M | 1.34% |
124,255
+4,312
| +4% | +$172K |
2017 Q4
9 quarters
|
|
|
ARNA
25
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.58M | 1.2% |
85,153
-4,204
| -5% | -$193K |
2019 Q3
2 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Sio Capital Management held 104 positions worth $298M, down 29% from $420M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Sio Capital Management's Q1 2020 filing shows 36 new, 13 increased, 16 reduced and 35 closed positions. Its largest new stake was Amgen: 106,069 shares worth $21.5M. The largest sale was Medtronic, an estimated $16.7M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.
- Sio Capital Management's largest Q1 2020 buy was Amgen: 106,069 shares worth $21.5M.
- Sio Capital Management added most to McKesson in Q1 2020, an estimated $9.36M increase.
- Sio Capital Management's biggest Q1 2020 reduction was Trillium Therapeutics Inc., cutting an estimated $8.82M.
- Sio Capital Management fully exited Medtronic in Q1 2020, selling an estimated $16.7M.
- Sio Capital Management's ten largest holdings make up 50% of its $298M portfolio in Q1 2020.
- Sio Capital Management opened 36 new positions and closed 35 in Q1 2020.
- Sio Capital Management's portfolio value fell 29% quarter-over-quarter to $298M.
Based on Sio Capital Management's 13F filing for Q1 2020, filed 15 May 2020.